Updates to Authorised Prescriber (AP) scheme requirements when accessing MDMA and psilocybine

Outcomes published

We have published the outcomes from the targeted consultation, roundtable and stakeholder discussions reviewing certain Authorised Prescriber (AP) scheme requirements for accessing MDMA and psilocybine on our consultation hub.

The recommendations focus on clarifying psychiatrist competency requirements, therapy team composition, prescriber oversight and treatment site standards.

Our recommendations aim to achieve a balance between facilitating appropriate access to the emerging unapproved psychedelic treatments while ensuring strong safeguards are in place to protect patient safety.

See MDMA and psilocybine for information about how we regulate MDMA and psilocybine and how access occurs under the Authorised Prescriber (AP) scheme.